Myeloablative allogeneic HSCT from an HLA-matched sibling or haploidentical donor, or using cord blood, peripheral blood, or bone marrow is recommended for treating SCD in patients with the Hb SS or Hb Sβ0 genotypes experiencing severe vaso-occlusive complications despite HU treatment. The gene discussed is GSTM1; the disease is Schnyder corneal dystrophy.